

DAFTAR PUSTAKA

- Adhika O. A. Fibrosis Hati. *Jurnal Kedokteran Maranatha*. 2009. 8(2). 198-210.
- Aggarwal B. B., Surh Y. J., Shishodia S. 2007. *The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease*. 1st Ed., Springer, India, p. 436-437
- Anom T. I., Wibawa I. D. N. Pendekatan Diagnosis dan Terapi Fibrosis Hati. *Journal of Internal Medicine*. 2010. 11(1): 57-67.
- Angulo P., Hui J. M., Marchesini G., Bugianesi E., George J., Farrell J. C., Enders F., Saksena S., Burt A. D., Bida J. P., Lindor K., Sanderson S. O., Lenzi M., Adams L. A., Kench J., Therneau T. M., Day C. P. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. *Hepatology*. 2007. 45(4): 846-854.
- Bataller R., Branner D. A., Liver Fibrosis. *The Journal of Clinical Investigation*. 2005. 115(2): 209-218.
- Bedossa P., Poynard T. An Algorithm for the Grading of Activity in Chronic Hepatitis C. *Hepatology*. 1996. 24(2): 289-293.
- Burgos-Moron E., Calderon-Montano J. M., Salvador J., Robles A., Lopez-Lazaro M. The darkside of curcumin. *International Journal of Cancer*. 2010. 126: 1771-1775.
- Dong C. Th17 cells in development: an updated view of their molecular identify and genetic programming. *Nature Review Immunology*. 2008. 8: 337-348.
- Du W. J., Zhen J. H., Zeng Z. Q., Zheng Z. M., Xu Y., Qin L. Y., Chen S. J. Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. *Diagnostic Pathology*. 2013. 8(40): 1-7.
- Fu Y., Zheng S., Lin J., Ryerse J., Chen A. Curcumin Protects the Rat Liver from CCl₄-Caused Injury and Fibrogenesis by Attenuating Oxidative Stress and Supressing Inflammation. *Molecular Pharmacology*. 2008. 73(2): 399-409.

- Espinoza Y. R., Muriel P. Pharmacological actions of curcumin in liver diseases or damage. *Liver International*. 2009. 29(10): 1457-1466.
- Gandhi C. R., Pinzani M. 2015. *Stellate Cells in Health and Disease*. 1st Ed., Academic Press, London, p. 41-55.
- Ghanny M., Hoofnagle J. H., 2014. *Harrison's gastroenterology and hepatology*, EGC, Jakarta, p. 290-298.
- Hammerich L., Heymann F., Tacke F. Role of IL-17 and Th17 in Liver Diseases. *Clinical and Developmental Immunology*. 2010. Vol. 2011: 1-6.
- Hammerich L., Tacke F. Role of gamma-delta T cells in liver inflammation and fibrosis. *World Journal of Gastrointestinal Patophysiology*. 2014. 5(2): 107-113.
- Henderson N. C., Iredale J. P. Liver Fibrosis: cellular mechanisms of progression and resolution. *Clinical Science*. 2007. 112(5): 265-280.
- Hutahean R., Ali R. H., Loho E. Hubungan Gambaran USG Pada Penderita Sirosis Hati dengan Fibrosis Skor di Bagian Radiologi RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2013 – Desember 2013. *Jurnal E – Clinic*. 2014. 2(1): 2-3.
- Keaveny A. P., Cardenas A. 2015. *Complication of Cirrhosis*. 1st Ed., Springer, New York, p. 3-12.
- Key M. 2006. *Immunohistochemical Staining Methods*. 4th Ed., Dako, California, p. 55
- Khedr N. F., Khedr E. G. Antioxidant and Anti-inflammatory Effects of Curcumin on CCl₄ – induced Liver Fibrosis in Rats. *American Journal of Biomedical Sciences*. 2014. 6(3): 191-200.
- Lafdil F., Miller A. M., Ki S. H., Gao B. Th17 cells and their associated cytokines in liver diseases. *Cellular and Molecular Immunology*. 2010. 7: 250-254

Lemmers A., Moreno C., Gustot T., Marechal R., Degre D., Demetter P., Nadai P., Geerts A., Quertinmont E., Vercruysse V., Moine O. L., Deviere J. The Interleukin-17 Pathway Is Involved in Human Alcoholic Liver Disease. *Hepatology*. 2009. 49(2): 646-657.

Li L., Hu Z., Li W., Hu M., Ran J., Chen P., Sun Q. Establishment of a Standardized Liver Fibrosis Model with Different Pathological Stages in Rats. *Gastroenterology Research and Practice*. 2012. Vol. 2012: 1-6.

Liu X., Xu J., Brenner D. A., Kisseleva T. Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. *Current Pathobiology Reports*. 2013. 1(3): 209-214.

Ma. H. Y., Xu J., Liu X., Zhu Y., Gao B., Karin M., Tsukamoto H., Jeste D. V., Grant I., Roberts A. J., Contet C., Geoffroy C., Zheng B., Brenner D., Kisseleva T. The Role of IL-17 Signaling in Regulation of the Liver-Brain Axis and Intestinal Permeability in Alcoholic Liver Disease. *Current Pathobiology Reports*. 2016. 4(1): 27-35.

Marra F., Tacke F. Roles for Chemokine in Liver Disease. *Gastroenterology*. 2014. 147(3): 577-594.

McPherson S., Stewart S. F., Henderson E., Burt A. D., Day C. P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut*. 2010. 59(9): 1265-1269.

Meng F., Wang K., Aoyama T., Grivennikov S. I., Paik Y., Scholten D., Cong M., Iwaisako K., Liu X., Zhang M., Osterreicher C. H., Stickel F., Ley K., Brenner D. A., Kisseleva T. Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cell Exacerbates Liver Fibrosis in Mice. *Gastroenterology*. 143: 765-776.

Panjaitan R. G. P., Handharyani E., Chairul., Masriani., Zakiah Z., Manalu W. Pengaruh Pemberian Karbon Tetraklorida Terhadap Fungsi Hati dan Ginjal Tikus. *Makara Kesehatan*. 2007. 11(1): 11-16.

Pellicoro A., Ramachandran P., Iredale J. P., Fallowfield J. A. Liver fibrosis and repair: immuno regulation of wound healing in a solid organ. *Nature Review Immunology*. 2014. 14(3): 181-194.

Pinzani M., Rombouts K. Liver Fibrosis: from the bench to clinical targets. *Digestive and Liver Disease*. 2004. 36(4): 231-242.

Purba E. R., Martosupono M., 2009. Kurkumin Sebagai Senyawa Antioksidan in A.Setiawan, A.I.Kristijanto, F.S.Rondenuwu, D.B.Nugroho, W.H.Kristiyanto (Eds), *Prosiding Seminar Nasional Sains dan Pendidikan Sains IV*, p. 607-621.

Rohmatin A. R., Susetyarini E., Hadi S., 2015. Kerusakan Sel Hepar Tikus Putih Jantan (*Rattus novergicus*) yang di Induksi Karbon Tetraklorida (CCl₄) setelah Diberi Ekstrak Etanol Bawang Dayak (*Eleutherine palmifolia* Merr.) in B.A.Prayitno, A.Saputra (Eds), *Prosiding Seminar Nasional Biologi*, p. 942-947.

Schuppan D., Kim Y. O. Evolving therapies for liver fibrosis. *The Journal of Clinical Investigation*. 2013. 123(5): 1887-1901.

Simanjuntak P. Studi Kimia dan Farmakologi Tanaman Kunyit (*Curcuma longa* L) sebagai Tumbuhan Obat Serbaguna. *Jurnal Ilmu Pertanian "Agrium"*. 2012. 17(2): 103-107.

Sudoyo A. W., Setiyohadi B., Alwi I., Simadibrata K., Setiati S., Syam A. F. 2014. *Buku Ajar Ilmu Penyakit Dalam*, 6th Ed., Interna Publishing, p. 1978-1983.

Sulaiman A., Akbar N., Lesmana L. A., Noer M. S. 2007. *Buku Ajar Ilmu Penyakit Hati*, 1st Ed., Jayabadi.

Suvarna K. S., Layton C., Bancroft J. D. 2012. *Bancroft's Theory and Practice of Histological Techniques*. 7th Ed., Elsevier Health Sciences, p. 175-176.

Tan Z., Qian X., Jiang R., Liu Q., Wang Y., Chen C., Wang X., Ryffel B., Sun B. IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation. *The Journal of Immunology*. 2013. 191(4): 1835-1844.

Tato C. M., O'Shea J. J. Immunology: What does it mean to be just 17?. *Nature Review Immunology*. 2006. 441: 166-168.

Wahyudi A. Pengaruh Penambahan Kurkumin Dari Rimpang Temu Giring pada Aktivitas Antioksidan Asam Askorbat dengan Metode FTC. *Akta Kimia Indonesia*. 2006. 2(1): 37-40.

Wang L., Chen S., Xu K. IL-17 expression is corelated with hepatitis B-related liver disease and fibrosis. *International Journal of Molecular Medicine*. 2011. 27(3): 385-392.

Wang P., Koyama Y., Liu X., Xu J., Ma H. Y., Liang S., Kim I. H., Brenner D. A., Kisseleva T. Promising Therapy Candidates for Liver Fibrosis. *National Center for Biotechnology Information*. 2016. 7(47): 1-9

Zheng S., Chen A. Activation of PPAR γ is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cell in vitro. *Biochemical Journal*. 2004. 384(1): 149-157.

Zhou Y., Zheng S., Lin J., Zhang Q. J., Chen A. The Interruption of PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPAR γ in rat activated hepatic stellate cell in vitro. *Laboratory Investigation*. 2007. Vol. 87: 488-498.

Ziol M., Luca A. H., Kettaneh A., Christidis C., Mal F., Kazemi F., Ledinghen V., Marcellin P., Dhumeaux D., Trinchet J. C., Beaugrand M. Noninvasive Assesment of Liver Fibrosis by Measurement of Stiffness in Patients with Chronic Hepatitis C. *Hepatology*. 2005. 41(1): 48-54